Jazz Pharmaceuticals (JAZZ) Retained Earnings (2010 - 2026)

Jazz Pharmaceuticals' Retained Earnings history runs 17 years deep, the most recent figure standing at -$651.0 million for Q1 2026.

• In Q1 2026, Retained Earnings fell 162.91% year-over-year to -$651.0 million; the TTM figure through Mar 2026 stood at -$651.0 million (down 162.91% YoY), while the FY2025 annual figure was $646.1 million, up 168.18% from the prior year.
• Retained Earnings was -$651.0 million for Q1 2026 at Jazz Pharmaceuticals, down from $646.1 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $1.0 billion in Q1 2025 to a low of -$1.6 billion in Q3 2022.
• Historically, Retained Earnings has averaged -$2.1 million across 5 years, with a median of $442.7 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Retained Earnings plunged 479.27% in 2022, then soared 188.15% in 2024.
• A 5-year view of Retained Earnings shows it stood at $733.6 million in 2022, then climbed by 19.78% to $878.7 million in 2023, then sank by 207.85% to -$947.7 million in 2024, then surged by 168.18% to $646.1 million in 2025, then sank by 200.76% to -$651.0 million in 2026.
• The last three Retained Earnings figures came in at -$651.0 million (Q1 2026), $646.1 million (Q4 2025), and $442.7 million (Q3 2025), per Business Quant data.